MAKE SURE YOUR DENTIST IS AN ADA MEMBER!: ADA Members Adhere to Strict Code of Ethics and Conduct. You should make sure you are SEEING AN ADA MEMBER DENTIST! Visit ADA Find-A-Dentist to Find One Near YOU
Ninth District Headquarters Office - Hawthorne, NY

2025 Ninth District President

Dr. Renuka Bijoor

ADA Update: a new login experience

We’re updating how you log in to your NYSDA and ADA account.

RENEW YOUR MEMBERSHIP TODAY!

3 EASY WAYS TO PAY 1 ONLINE: nysdental.org/renew 2 MAIL: Return dues stub and payment 3 PHONE: 1-800-255-2100

Member Assistance Program (MAP)

Life comes with challenges, but your new Member Assistance Program (MAP) is here to help. This free, confidential benefit is available to you and your household, offering resources and services to support mental health, reduce stress, and make life easier.

Welcome to the Ninth District Dental Association

The Ninth District Dental Society was formed in 1909 and renamed to the Ninth District Dental Association in 2002. We have a membership of over 1500 dentists in 5 counties: Westchester, Rockland, Dutchess, Orange and Putnam.

In its quest to serve both the public and the profession, the Ninth District embodies the highest ideals.

The mission of the 9th District Dental Association is to serve and support its members and the public by improving the oral health of our community through Advocacy, Continuing Education and Camaraderie.



Meet Member Dentists, Residents, and Students!

FREE & OPEN TO ALL!

"Health is Wealth"

Summer Wellness Event

 Wednesday, July 30, 2025

6:30-8:30pm 

Hudson River Park
240 W. Main Street
Tarrytown, NY 10591

All 9th Members, New Dentists, Residents, and Touro Dental Students are invited
with their Spouse/Partner and Children!

Latusion Food Truck, Standing Yoga, and Music at

Beautiful Scenic Hudson River Park!
Free parking after 6pm, DO NOT Park in Lot E.

 

Afterwards enjoy a nice sunset walk along the river or drinks at one of the

close-by river view restaurants.


To Register please click here 
or call HQ 914-747-1199.

 

We Hope to See You There!!

 B. J. Mistry, D.D.S.
Chair, Substance Abuse & Wellness Committee

Lana Hashim, D.D.S.
Chair, New Dentist Committee

Renuka Bijoor, D.D.S., M.P.H.President

Co-Sponsors

Feldman Kieffer 

M&T Bank

(name is link to website)


Latest News Around the Tripartite

FDA Makes Changes to Opioid Drug Labeling

Jul 31, 2025

Per the notice below, the United States Food and Drug Administration (FDA) is requiring major changes to the labeling of opioids to emphasize risks.

FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks

Labeling change will affect all opioid pain medications and support more informed decision-making

The U.S. Food and Drug Administration is requiring safety labeling changes to all opioid pain medications to better emphasize and explain the risks associated with their long-term use.  These changes follow a public advisory committee meeting in May that reviewed data showing serious risks—such as misuse, addiction, and both fatal and non-fatal overdoses—for patients who use opioids over long periods.

“The death of almost one million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,” said FDA Commissioner Marty Makary, M.D., M.P.H.  “This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and post-market monitoring so that nothing like this ever happens again.”

Tragically, the new drug application for OxyContin was initially approved without study data supporting its long term use to treat pain in many patient populations for which it has been prescribed.  The updated labeling change reflects robust data from two large FDA-required observational studies, called postmarketing requirements (PMR) 3033-1 and 3033-2, which recently provided new data on how long-term opioid use can lead to serious side effects.  After reviewing those results, public comments, medical research and recognizing the absence of adequate and well-controlled studies on long-term opioid effectiveness, the FDA decided to require safety labeling changes to help health care professionals and patients make treatment decisions rooted in the latest evidence.

“I know firsthand how devastating addiction is—not just for individuals, but for entire families and communities,” said HHS Secretary Robert F. Kennedy, Jr.  “Today’s FDA action is a long-overdue step toward restoring honesty, accountability, and transparency to a system that betrayed the American people.”

FDA has required an additional prospective, randomized, controlled clinical trial to directly examine the benefits and risks of long-term opioid use.  The Agency will be closely monitoring the progress of this clinical trial to ensure its timely completion.

The labeling changes will include the following updates:

  • Clearer Risk Information: A summary of study results showing the estimated risks of addiction, misuse, and overdose during long-term use.
  • Dosing Warnings: Stronger warnings that higher doses come with greater risks, and that those risks remain over time.
  • Clarified Use Limits: Removing language which could be misinterpreted to support using opioid pain medications over indefinitely long duration.
  • Treatment Guidance: Labels will reinforce that long-acting or extended-release opioids should only be considered when other treatments, including shorter-acting opioids, are inadequate.
  • Safe Discontinuation: A reminder not to stop opioids suddenly in patients who may be physically dependent, as it can cause serious harm.
  • Overdose Reversal Agents: Additional information on medicines that can reverse an opioid overdose.
  • Drug Interactions: Enhanced warning about combining opioids with other drugs that slow down the nervous system—now including gabapentinoids.
  • More Risks with Overdose: New information about toxic leukoencephalopathy—a serious brain condition that may occur after an overdose.
  • Digestive Health: Updates about opioid-related problems with the esophagus.

The FDA sent letters to the relevant applicants outlining the required changes.  The companies will have 30 days to submit their labeling updates to the FDA for review.  More information is available in the FDA’s Drug Safety Communication.


Latest News Around the Ninth


Around the Ninth District